ASCERTAIN: Improving access to innovative health technologies

Healthcare systems in Europe and beyond face challenges in ensuring affordable access to innovative health technologies (including pharmaceuticals). The Horizon Europe-funded ASCERTAIN project aims to develop new models for pricing, assessment (HTA) and financing of these health technologies. The Pharmacoeconomics Department at Gesundheit Österreich GmbH is part of this four-year project led by Erasmus University Rotterdam and leads a work package focusing on the development of new (fair) pricing models and approaches for innovative healthcare technologies.

Objective

ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and ReimbursemenT models to Appraise INnovative health technologies) addresses the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe. ASCERTAIN aims to enhance current methods of (value-based) pricing, cost-effectiveness modeling, threshold-setting, reimbursement, and payment, to set affordable prices, and to facilitate a cyclic assessment of broader societal benefits including costs and risks.

The Pharmacoeconomics Department at Gesundheit Österreich GmbH co-lead a work package focusing on developing new approaches for pricing innovative technologies that aim to find a balance between improving patient access and stimulating entrepreneurship.

Research output

Presentations and posters at scientific conferences with contributions from members of the Pharmacoeconmics Department at GÖG

Webinars with contributions from members of the Pharmacoeconmics Department at GÖG

Further information

Contact

Should you have any questions, please do not hesitate to contact the project team (maximilian.salcher@goeg.at / timea.helter@goeg.at).